Pfizer and BioNTech have formally asked for FDA approval of a third dose of their COVID-19 vaccine BNT162b2 in people aged over 16, as the US prepares to get its booster campaign underway.

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

Fox News contributor Dr. Marty Makary was officially confirmed to lead the FDA in Trump's second administration after a vote ...

(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

The following is the transcript of an interview with Dr. Scott Gottlieb, former FDA commissioner, that aired on "Face the ...

On this "Face the Nation with Margaret Brennan" broadcast, National Security Adviser Mike Waltz and Rep. Rand Paul join ...

News Wrap: Pfizer says booster offers protection against omicron variant In our news wrap Wednesday, drug maker Pfizer says its double-dose vaccine — plus a booster — may offer significant ...

People fully vaccinated against hepatitis B who are not immunocompromised can expect sustained immunity throughout their ...

The CDC also recommends that people who had an allergic reaction to the first MMR vaccine hold off on getting the second dose ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway and clinical sites confirmed  Additional data evaluating GEO-CM04S1 as ...

After a cardiovascular event, it proves difficult to maintain a healthier, more active lifestyle over the long term. Although ...